



Fig. 10. Induction of GDNF synthesis and release by rasagiline in SHSY-5Y human dopamine neuroblastoma cells (ref. 146).

IKK) composed of IKK- α , - β and - γ . When the IKK complex is phosphorylated, I κ B and I κ B β are cleaved at two serine residues in the N-terminal region and dissociated, resulting in the activation of NF- κ B. Sulfasalazine, an inhibitor of IKK- α and - β (154), inhibits the rasagiline-induced NF- κ B activation and the NCI 1420 1-8 induced GDNF protein simultaneously (146). These results indicate that rasagiline may activate NF- κ B through the IKK pathway, resulting in GDNF synthesis. Whether rasagiline directly or indirectly affects the IKK components through activation of upstream kinases in the cells remains to be elucidated.

Rasagiline activates PKC and Erk1/2 MAP kinase (101, 124) in a time- and concentration-dependent manner, a property directly dependent on the propargylamine moiety of this drug, since propargylamine itself has an identical effect with the same potency (101). Activation of PKC by rasagiline is linked to its neuroprotective activity, since inhibitors of ERK and PKC prevent PKC pathway-dependent Bcl-2-induced neuroprotection, thus eliminating the neuroprotective activity of rasagiline (84, 125). This would be compatible with the recent finding indicating a link between PKC and Bcl-2. The results suggest that rasagiline targets the Bcl-2 antiapoptotic family and the protein regulating signal

transduction in the MAP kinase system, as well as transcription factors. The mechanism of these interactions is not yet fully known, but PKC activation may have a role that needs to be investigated. Although the ability of rasagiline to activate NF- κ B and increase GDNF is concentration dependent, this action, as well as its ability to be neuroprotective and activate Bcl-2 and PKC, exhibits biphasic curves. Rasagiline has also been shown to exhibit an inverted U-shaped relationship in its neuroprotective function (42, 67) and in its induction of Bcl-2 (99). Tumor necrosis factor (TNF)- α , reactive oxygen species H₂O₂ and β -amyloid all activate NF- κ B according to an inverted U-shaped dose-response-dependent curve. While at the low concentration, TNF- α is neuroprotective in correlation with NF- κ B activation, in contrast, at the high concentration it is neurotoxic (155). The mechanism behind the inverted U-shaped type of concentration-activity relationship concerning NF- κ B remains to be fully elucidated. Such phenomena are not unusual since dopamine, apomorphine, melatonin and green tea polyphenol exhibit exactly the same type of action in SHSY-5Y cells. For these compounds, it has been shown that at low concentrations, their neuroprotective activity is related to activation of the antiapoptotic bcl-2 family genes and proteins. In





contrast, at high concentrations—when they are pro-apoptotic and induce cell death—they activate pro-apoptotic Bad, Bax and other cell-inducing genes (100). GDNF is now proposed as an agent for rescuing declining dopamine neurons in Parkinson's disease, as supported by its effectiveness in animal and cellular models (156). Lentiviral-delivered GDNF was reported to rescue dying dopamine neurons in a monkey model of Parkinson's disease prepared with *N*-methyl-4-phenyl 1,2,3,6-tetrahydropyridine (MPTP) (157). Infusion of GDNF protein by an implanted intracerebroventricular catheter failed to improve symptoms in parkinsonian patients (158). However, it was recently reported that the direct infusion of GDNF into the putamen of parkinsonian patients improved clinical symptoms and fluorodopa uptake to the dopamine terminal (159). These results indicate that GDNF supplemental therapy requires further technical improvement for its effective administration. If rasagiline, which is currently undergoing FDA revision for approval as an antiparkinsonian drug (26), can also increase endogenous GDNF in the human brain, as shown here with SH-SY5Y cells, it may be a more practical therapy to prevent dopamine neuron cell death. In conclusion, rasagiline and related propargylamines are possible neuroprotective agents, and a part of their pharmacological action may be due to the induction of pro-survival genes through NF- κ B activation, antiapoptotic Bcl-2 family protein production and inhibition of GAPDH translocation from cytoplasm into the nucleus (73). The activation of transcription factors related to antiapoptotic proteins, GDNF and bcl-2 (Maruyama *et al.*, in preparation) by propargylamines might enable us to suppress neuronal death in neurodegenerative disorders in general. Clinical trials with rasagiline are awaiting final evaluation of the efficacy data to determine the compound's ability to protect specified neurons from degeneration.

Conclusion

Pharmacologically and biochemically, rasagiline is demonstrating neuroprotective activity *in vitro* and *in vivo*. The molecular aspect of this neuroprotective property has now been demonstrated by conventional methods and by genomic and proteomic analysis to involve several factors, including downregulation of pro-apoptotic Bcl-2 family proteins that regulate the mitochondrial-dependent cell survival mechanism on the one hand, and activation of the transcription factor NF- κ B and the PKC-


dependent MAP kinase pathway that regulate production of neurotrophic factors, including GDNF, BDNF and nerve growth factor (84, 125, 146). Thus, rasagiline may have pharmacological activities that initiate neuroprotection, as well as neuronal plasticity related to the activation of Bcl-2 and PKC. It is apparent that Bcl-2 and PKC pathway-dependent neuroprotective and neurotrophic activities of rasagiline are closely linked, since both ERK and PKC inhibitors prevent these activities (84, 99). Whether this neuroprotective activity can be translated into the treatment of Parkinson's and Alzheimer's disease subjects remains to be determined by PET and SPECT in clinical studies. However, it should be noted that results from recent double-blind delayed-start controlled studies with rasagiline suggest that it may exert disease-modifying action (27).


Acknowledgment

The support of Technion Research and Development (Haifa, Israel), the National Parkinson's Foundation (Miami, Florida, USA), Teva Pharmaceutical Co. (Netanya, Israel), the Stein Foundation and the Friedman Foundation (Philadelphia, Pennsylvania, USA) are gratefully acknowledged. Permission to use figures from Golding Parkinson's Research Fund and from Technion, as well as from articles appearing in *Neuropharmacology*, *Biochemical Pharmacology*, *British Journal of Pharmacology* and *Expert Reviews of Neurotherapeutics*, are gratefully acknowledged.


References

1. Collins, G.G., Sandler, M., Williams, E.D., Youdim, M.B. *Multiple forms of human brain mitochondrial monoamine oxidase*. *Nature* 1970, 225: 817-20.
2. Squires, R.F. *Multiple forms of monoamine oxidase in intact mitochondria as characterized by selective inhibitors and thermal stability: a comparison of eight mammalian species*. *Adv Biochem Psychopharmacol* 1972, 5: 355-7.
3. O'Carroll, A.M., Fowler, C.J., Phillip, J.P., Tobia, I., Tipton, K.F. *The deamination of dopamine by human brain monoamine oxidase. Specificity for the two forms in seven brain regions*. *Naunyn Schmiedebergs Arch Pharmacol* 1983, 322: 198-207.
4. Knoll and Magyar. *Some puzzling pharmacological effects of monoamine oxidase inhibitors*. *Adv Biochem Psychopharmacol* 1972, 5: 393-408.







5. Birkmayer, W., Riederer, P., Youdim, M.B., Linauer, W. *The potentiation of the anti akinetik effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil.* J Neural Transm 1975, 36: 303-26.
6. Birkmayer, W., Riederer, P., Ambrozi, L., Youdim, M.B. *Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study.* Lancet 1977, 1: 439-43.
7. Lees, A.J., Shaw, K.M., Kohout, L.J. et al. *Deprenyl in Parkinson's disease.* Lancet 1977, 2: 791-5.
8. Parkinson Study Group (Datatop). *Selegiline and Parkinson's disease.* N Engl J Med 1989, 321: 1364-71.
9. Birkmayer, W., Knoll, J., Riederer, P., Youdim, M.B., Hars, V., Marton, J. *Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: A long-term study.* J Neural Transm 1985, 64: 113-27.
10. Riederer, P., Rinne U.K. *Selegiline in Parkinson's Disease: An update.* Mov Disords 1992, 8 (Suppl. 1): 51-44.
11. Maycock, A.L., Abeles, R.H., Salach, J., Singer, T.P. *The action of acetylenic inhibitors on mitochondrial monoamine oxidase: Structure of the flavin site in the inhibited enzyme.* Ciba Foundation Symposium, Elsevier, Amsterdam 1976, 39: 33-49.
12. Youdim, M.B.H. *The active centers of monoamine oxidase types A and B, binding with ¹⁴C-clorgyline and ¹⁴C-deprenyl.* J Neural Transm 1978, 43: 199-208.
13. Reynolds, G.P., Riederer, P., Sandler, N.R., Jellinger, K., Seemali, D. *Amphetamine and 2-phenylethylamine in post mortem Parkinson brains after l-deprenyl administration.* J Neural Transm 1978, 3: 271-8.
14. Green, A.R., Youdim, M.B. *Effects of monoamine oxidase inhibition by clorgyline, deprenil or tranlycypromine on 5-hydroxytryptamine concentrations in rat brain and hyperactivity following subsequent tryptophan administration.* Br J Pharmacol 1975, 55: 415-22.
15. Simpson, L.L. *Evidence that deprenyl, a type B monoamine oxidase inhibitor is an indirectly acting sympathomimetic amine.* Biochem Pharmacol 1978, 27: 1591-5.
16. Finberg, J.P.M., Tenne, M., Youdim, M.B.H. *Tyramine antagonistic properties of AGN 1135, an irreversible inhibitor of monoamine oxidase type B.* Br J Pharmacol 1981, 73: 65-74.
17. Youdim, M.B.H., Finberg, J.P.M., Levy, R. et al. *R-Enantiomers of N-propargyl-aminoindan compounds. Their preparation and pharmaceutical composition containing them.* US Patent 1995, 5: 457, 133; NCI 1420, 1-8.
18. Sterling, J., Veinberg, A., Lerner, D. et al. *(R) (+)-N-propargyl-1-aminoindan (rasagiline) and derivatives: Highly selective and potent inhibitors of monoamine oxidase B.* J Neural Transm Suppl 1998, 52: 301-5.
19. Sterling, J., Herzig, Y., Goren, T. et al. *Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease.* J Med Chem 2002, 45: 5260-79.
20. Sabbagh, A., Youdim, M.B.H. *Selective inhibition of monoamine oxidase type B by propargyl-containing drugs.* Israel J Med Sci 1978, 14: 1097.
21. Kalir, A., Sabbagh, A., Youdim, M.B.H. *Selective "suicide" acetylenic and reversible inhibitors of monoamine oxidase A and B.* Br J Pharmacol 1981, 73: 55-64.
22. Youdim, M.B.H., Gross, A., Finberg, J.P.M. *Rasagiline [N-Propargyl-1R(+)-aminoindant], A selective and potent inhibitor of mitochondrial monoamine oxidase B.* Br J Pharmacol 2001, 132: 500-6.
23. Youdim, M.B., Finberg, J.P. *MAO type B inhibitors as adjunct to L-dopa therapy.* Adv Neurol 1987, 45: 127-36.
24. Finberg, J.P., Wang, J., Bankiewicz, K., Harvey-White, J., Kopin, I.J., Goldstein, D.S. *Increased striatal dopamine production from L-DOPA following selective inhibition of monoamine oxidase B by R(+)-N-propargyl-1-aminoindan (rasagiline) in the monkey.* J Neural Transm 1998, 52: 279-85.
25. Finberg, J.P., Lamensdorf, I., Weinstock, M., Schwartz, M., Youdim, M.B. *Pharmacology of rasagiline (N-propargyl-1R-aminoindan).* Adv Neurol 1999, 80: 495-9.
26. Parkinson Study Group. *A controlled trial of rasagiline in early Parkinson disease: The TEMPO Study.* Arch Neurol 2002, 59: 1937-43.
27. Parkinson Study Group. *A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease.* Arch Neurol 2004, 61: 561-6.
28. Finberg, J.P.M., Youdim, M.B.H. *Modification of blood pressure and nictitating membrane re-*







- response to sympathetic amines by selective monoamine oxidase inhibitors of types A and B in the cat. *Br J Pharmacol* 1985, 85: 541-6.
29. Rabey, J.M., Sagi, I., Huberman, M. et al.; Rasagiline Study Group. *Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: A double-blind study as adjunctive therapy to levodopa*. *Clin Neuropharmacol* 2000, 23: 324-30.
 30. Largo Study Group, 2003 (unpublished data).
 31. Parkinson Study Group. *A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations. The PRESTO Study*. *Arch Neurol* 2005, 62: 241-8.
 32. Salach, J., Detmer, K., Youdim, M.B.H. *The reaction of bovine and rat liver monoamine oxidase with [¹⁴C]-clorgyline and [¹⁴C]-deprenyl*. *Mol Pharmacol* 1978, 16: 234-41.
 33. Youdim, M.B.H., Finberg, J.P.M., Tipton, K.F. *Monoamine Oxidases*. In: Weiner, N., Trendelenburg, U. (Eds.). *Handbook of Experimental Pharmacology Catecholamine II*. Springer-Verlag, Berlin 1998, pp. 415-58.
 34. Kearney, F.B., Salach, J.I., Walker, W.H. et al. *The covalently bound flavin of hepatic monoamine oxidase I. Isolation and sequence of a flavin peptide and evidence for binding to the 8-position*. *Eur J Biochem* 1971, 24: 321-7.
 35. Bach, A.W.J., Lan, N.C., Johnson, D.L. et al. *cDNA cloning of human liver monoamine oxidase A and B: Molecular basis of differences in enzymatic properties*. *Proc Nat Acad Sci USA* 1988, 85: 4934-8.
 36. Salach, J., Singer, T.P., Yaunobu, K.T., Monamura, N., Youdim, M.B.H. *Cysteinyl flavin in monoamine oxidase from the central nervous system*. *Ciba Foundation Symposium*, Elsevier, Amsterdam 1976, 39: 49-57.
 37. Holzbauer, M., Youdim, M.B. *The oestrous cycle and monoamine oxidase activity*. *Br J Pharmacol* 1973, 48: 600-8.
 38. Fowler, J.S., Volkow, N.D., Logan, J. et al. *Slow recovery of human brain MAO B after deprenyl (selegiline) withdrawal*. *Synapse* 1994, 18: 86-93.
 39. Youdim, M.B., Banerjee, D.K., Kelner, K., Offutt, L., Pollard, H.B. *Steroid regulation of monoamine oxidase activity in the adrenal medulla*. *FASEB J* 1989, 3: 1753-9.
 40. Youdim, M.B., Riederer, P. *The relevance of glial monoamine oxidase-B and polyamines to the action of selegiline in Parkinson's disease*. *Mov Disord* 1993, 8 (Suppl. 1): S8-S13.
 41. Youdim, M.B., Tipton, K.F. *Rat striatal monoamine oxidase-B inhibition by l-deprenyl and rasagiline: Its relationship to 2-phenylethylamine-induced stereotypy and Parkinson's disease*. *Parkinsonism Relat Disord* 2002, 8: 247-53.
 42. Youdim, M.B.H., Wadia, A., Tatton, N.A., Weinstein, M. *The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo*. *Ann NY Acad Sci* 2001, 939: 450-8.
 43. Gotz, M.E., Breithaupt, W., Sautter, J. et al. *Chronic TVP-1012 (rasagiline) dose-activity response of monoamine oxidases A and B in the brain of the common marmoset*. *J Neural Transm* 1998, 52 (Suppl.): 271-8.
 44. Riederer, P., Youdim, M.B. *Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl*. *J Neurochem* 1986, 46: 1359-65.
 45. Green, A.R., Tordoff, A., Mitchel, B., Youdim, M.B.H. *Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for degree of inhibition of enzyme necessary for increased function and activity of dopamine and 5-hydroxytryptamine*. *Br J Pharmacol* 1977, 60: 343-9.
 46. Riederer, P., Konradi, C., Schay, V. et al. *Localization of MAO-A and MAO-B in human brain: A step in understanding the therapeutic action of L-deprenyl*. *Adv Neurol* 1986, 45: 111-8.
 47. Neff, N.H., Gordis, C. *Neuronal monoamine oxidase: Specific enzyme types and their rates of formation*. *Adv Biochem Psychopharmacol* 1972, 5: 307-24.
 48. Della Corte, L., Tipton, K.F. *The turnover of the A and B-forms of monoamine oxidase in rat liver*. *Biochem Pharmacol* 1980, 29: 811-5.
 49. Finberg, J.P., Youdim, M.B. *Pharmacological properties of the anti-Parkinson drug rasagiline, modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours*. *Neuropharmacology* 2002, 43: 1110-18.
 50. Finberg, J.P., Tenne, M. *Relationship between tyramine potentiation and selective inhibition of monoamine oxidase types A and B in the rat vas deferens*. *Br J Pharmacol* 1982, 77: 13-21.
 51. Youdim, M.B.H. *Rasagiline - An anti-Parkinson drug with neuroprotective activity*. *Fut Drug Expert Neurotherap Rev* 2003, 3: 737-49.







52. Lamensdorf, I., Youdim, M.B., Finberg, J.P. *Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo.* J Neurochem 1996, 67: 1532-9.
53. Finberg, J.P., Takeshima, T., Johnston, J.M., Commissiong, J.W. *Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor.* Neuroreport 1998, 9: 703-7.
54. Lamensdorf, L., Youdim, M.B., Finberg, J.P. *Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo.* J Neurochem 1996, 67: 1532-9.
55. Lamensdorf, I., Porat, S., Simantov, R., Finberg, J.P. *Effect of low-dose treatment with selegiline on dopamine transporter (DAT) expression and amphetamine-induced dopamine release in vivo.* Br J Pharmacol 1999, 126: 997-1002.
56. Yang, H.Y., Neff, N.H. *Beta-phenylethylamine: A specific substrate for type B monoamine oxidase of brain.* J Pharmacol Exp Ther 1973, 187: 365-71.
57. Maitre, L., Delini-Stula, A., Waldmeier, P.C. *Relation between the degree of monoamine oxidase inhibition and some psychopharmacological responses to monoamine oxidase inhibitors.* Ciba Foundation Symposium, Elsevier, Amsterdam 1976, 39: 247-67.
58. Riederer, P., Youdim, M.B., Rausch, W.D., Birkmayer, W., Jellinger, K., Seemann, D. *On the mode of action of L-deprenyl in the human central nervous system.* J Neural Transm 1978, 43: 217-26.
59. Neff, N.H., Yang, H.Y., Fuentes, J.A. *The use of selective monoamine oxidase inhibitor drugs to modify amine metabolism in brain.* Adv Biochem Psychopharmacol 1974, 12: 49-57.
60. Janssens de Varebeke, P., Pauwels, G., Buyse, C. et al. *The novel neuropsychotropic agent milacemide is a specific enzyme-activated inhibitor of brain monoamine oxidase B.* J Neurochem 1989, 53: 1109-16.
61. Youdim, M.B., Riederer, P. *Dopamine metabolism and neurotransmission in primate brain in relationship to monoamine oxidase A and B inhibition.* J Neural Transm Gen Sect 1993, 91: 181-95.
62. Heikkila, R.E., Duvoisin, R.C., Finberg, J.P., Youdim, M.B.H. *Prevention of MPTP neurotoxicity by AGN1133 and AGN-1135, selective inhibitors of monoamine oxidase.* Eur J Pharmacol 1985, 116: 313-7.
63. Speiser, Z., Katzir, O., Rehavi, M., Zabarski, T., Cohen, S. *Sparing by rasagiline (TVP-1012) of cholinergic functions and behavior in the postnatal anoxia rat.* Pharmacol Biochem Behav 1998, 60: 387-93.
64. Speiser, Z., Levy, R., Cohen, S. *Effects of N-propargyl-1-(R)aminoindan (rasagiline) in models of motor and cognition disorders.* J Neural Transm Suppl 1998, 52: 287-300.
65. Huang, W., Chen, Y., Shohami, E., Weinstock, M. *Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse.* Eur J Pharmacol 1999, 366: 127-35.
66. Waibel, S., Reuter, A., Malessa, S., Blaugrund, E., Ludolph, A.C. *Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model.* J Neurol 2004, 251: 1080-4.
67. Blandini, F., Armentero, M.T., Fancellu, R., Blaugrund, E., Nappi, G. *Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease.* Exp Neurol 2004, 187: 455-9.
68. Ravina, B.M., Fagan, S.C., Hart, R.G. et al. *Neuroprotective agents for clinical trials in Parkinson's disease: A systematic assessment.* Neurology 2003, 22, 60: 1234-40.
69. Maruyama, W., Naoi, M. *Neuroprotection by (-)-deprenyl and related compounds.* Mech Ageing Dev 1999, 111: 189-200.
70. Maruyama, W., Youdim, M.B.H., Naoi, M. *Anti-apoptotic function of N-propargylamine-1(R)- and (S)-aminoindan, Rasagiline and TV1022.* Ann NY Acad Sci 2000, 939: 320-9.
71. Maruyama, W., Akao, Y., Youdim, M.B.H., Naoi, M. *Neurotoxins induce apoptosis in dopamine neurons: Protection by N-propargylamine 1(R)- and (S)-aminoindan, rasagiline and TV1022.* J Neural Transm 2000, 60: 171-86.
72. Maruyama, W., Boulton, A. A., Davis, B.A., Dostert, P., Naoi, M. *Enantio-specific induction of apoptosis by an endogenous neurotoxin, N-methyl(R)salsolinol, in dopaminergic SH-SY5Y cells: Suppression of apoptosis by N-(2-heptyl)-N-methylpropargylamine.* J Neural Transm 2001, 108: 11-24.
73. Maruyama, W., Akao, Y., Youdim, M.B., Davis, B.A., Naoi, M. *Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced*







- by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol. *J Neurochem* 2001, 78: 727-35.
74. Maruyama, W., Akao, Y., Carrillo, M.C., Kitani, K., Youdim, M.B., Naoi, M. *Neuroprotection by propargylamines in Parkinson's disease: Suppression of apoptosis and induction of pro-survival genes*. *Neurotoxicol Teratol* 2002, 24: 675-82.
75. Maruyama, W., Takahashi, T., Youdim, M., Naoi, M. *The anti-Parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells*. *J Neural Transm* 2002, 109: 467-81.
76. Youdim, M.B.H., Weinstock, M. *Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug, TV3326, [(N-propargyl)-(3R)aminoindan-5-yl]-ethyl methyl carbamate*. *Cell Mol Neurobiol* 2002, 21: 555-73.
77. Tatton, N.A. *Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease*. *Exp Neurol* 2000, 166: 29-43.
78. Tatton, W.G., Chalmers-Redman, R.M., Ju, W.J. et al. *Propargylamines induce anti-apoptotic new protein synthesis in serum- and nerve growth factor (NGF)-withdrawn, NGF-differentiated PC-12 cells*. *J Pharmacol Exp Therap* 2002, 301, 753-64.
79. Maruyama, W., Weinstock, M., Youdim, M.B., Nagai, M., Naoi, M. *Anti-apoptotic action of anti-Alzheimer drug, TV3326 [(N-propargyl)-(3R)-aminoindan-5-yl]-ethyl methyl carbamate, a novel cholinesterase- monoamine oxidase inhibitor*. *Neurosci Lett* 2003, 341: 233-6.
80. Maruyama, W., Akao, Y., Carrillo, M.C., Kitani, K., Youdim, M.B., Naoi, M. *Neuroprotection by propargylamines in Parkinson's disease: Suppression of apoptosis and induction of pro-survival genes*. *Neurotoxicol Teratol* 2002, 24: 675-82.
81. Parkinson Study Group. *Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease*. *N Engl J Med* 1993, 328: 176-83.
82. Abu-Raya, S., Blaugrund, E., Trembovler, V., Shilderman-Bloch, E., Shohami, E., Lazarovici, P. *Rasagiline, a monoamine oxidase-B inhibitor, protects NGF-differentiated PC12 cells against oxygen-glucose deprivation*. *J Neurosci Res* 1999, 58: 456-63.
83. Abu-Raya, S., Tabakman, R., Blaugrund, E., Trembovler, V., Lazarovici, P. *Neuroprotective and neurotoxic effects of monoamine oxidase-B inhibitors and derived metabolites under ischemia in PC12 cells*. *Eur J Pharmacol* 2002, 434: 109-16P.
84. Bar Am, O., Amit, T., Youdim, M.B.H. *Contrasting neuroprotective and neurotoxic actions of respective metabolites of antiparkinson drugs rasagiline and selegiline*. *Neurosci Lett* 2004, in press.
85. Speiser, Z., Mayk, A., Eliash, S., Cohen, S. *Studies with rasagiline, a MAO-B inhibitor, in experimental focal ischemia in the rat*. *J Neural Transm* 1999, 106: 59.
86. Oh, C., Murray, B., Bhattacharya, N., Holland, D., Tatton, W.G. *(-)-Deprenyl alters the survival of adult murine facial motoneurons after axotomy: Increases in vulnerable C57BL strain but decreases in motor neuron degeneration mutants*. *J Neurosci Res* 1994, 38: 64-74.
87. Youdim, M.B., Weinstock, M. *Novel neuroprotective anti-Alzheimer drugs with anti-depressant activity derived from the anti-Parkinson drug, rasagiline*. *Mech Ageing Dev* 2002, 123: 1081-6.
88. Carrillo, M.C., Minami, C., Kitani, K. et al. *Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the rat*. *Life Sci* 2000, 67: 577-85.
89. Youdim, M.B., Heldman, E., Pollard, H.B., Fleming, P., McHugh, E. *Contrasting monoamine oxidase activity and tyramine induced catecholamine release in PC12 and chromaffin cells*. *Neuroscience* 1986, 19: 1311-8.
90. Naoi, M., Maruyama, W., Akao, Y., Yi, H. *Mitochondria determine the survival and death in apoptosis by an endogenous neurotoxin, N-methyl(R)salsolinol, and neuroprotection by propargylamines*. *J Neural Transm* 2002, 109: 607-21.
91. Gassen, M., Lamensdorf, I., Armony, T., Finberg, J.P., Youdim, M.B. *Attenuation of methamphetamine induced dopaminergic neurotoxicity by flupirtine: Microdialysis study on dopamine release and free radical generation*. *J Neural Transm* 2003, 110: 171-82.
92. Pellegrini-Giampietro, D.E., Peruginelli, F., Meli, E. et al. *Protection with metabotropic glutamate 1 receptor antagonists in models of ischemic neuronal death: Time-course and mechanisms*. *Neuropharmacology* 1999, 38: 1607-19.







93. Sagi, Y., Mandel, S., Youdim, M.B.H. *Genomic and proteomic profiling of the neuroprotective mechanism of rasagiline in the mouse model of PD*. *Neural Plasticity* 2003, 10: 227.
94. Belzacq, A.S., Brenner, C. *The adenine nucleotide translocator: A new potential chemotherapeutic target*. *Curr Drug Targets* 2003, 7: 517-24, review.
95. Belzacq, A.S., Vieira, H.L., Kroemer, G., Brenner, C. *The adenine nucleotide translocator in apoptosis*. *Biochimie* 2002, 84: 167-76.
96. Belzacq, A.S., Vieira, H.L., Kroemer, G., Brenner, C. *The adenine nucleotide translocator in apoptosis*. *Biochimie* 2002, 84: 167-76.
97. Halestrap, A.P., McStay, G.P., Clarke, S.J. *The permeability transition pore complex: Another view*. *Biochimie* 2002, 84: 153-66.
98. Suleiman, M.S., Halestrap, A.P., Griffiths, E.J. *Mitochondria: A target for myocardial protection*. *Pharmacol Ther* 2001, 89: 29-46.
99. Akao, Y., Maruyama, W., Shimizu, S. et al. *Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan*. *J Neurochem* 2002, 82: 913-23.
100. Weinreb, O., Mandel, S., Youdim, M.B. *cDNA gene expression profile homology of antioxidants and their antiapoptotic and proapoptotic activities in human neuroblastoma cells*. *FASEB J* 2003, 17: 935-7.
101. Yogev-Falach, M., Amit, T., Bar-Am, O., Youdim M.B. *The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives in MAPK-dependent amyloid precursor protein processing*. *FASEB J* 2003, 17: 2325-7.
102. Bar Am, O., Amit, T., Weinreb, O., Yogev-Falach, M., Youdim, M.B.H. *The neuroprotective activity of rasagiline and its propargyl moiety is dependent on activation/gene expression of protein kinase C (PKC)*. *Neural Plasticity* 2003, 10: 183.
103. Weinreb, O., Bar Am, O., Chilag-Tamar, O., Amit, T., Youdim, M.B.H. *Gene and protein expression profiles of neuroprotective and anti-apoptotic action of rasagiline in PC-12 cell cultures*. *Neural Plasticity* 2003, 10: 238.
104. Constantini, L.C., Cole, D., Chaturvedi, P., Isacson, P. *Immunophilin ligands can prevent progressive dopaminergic degeneration in animal models of Parkinson's disease*. *J Eur Neurosci* 2001, 13: 1085-92.
105. Akao, Y., Maruyama, W., Yi, H., Shamoto-Nagai, M., Youdim, M.B., Naoi, M. *An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells*. *Neurosci Lett* 2002, 326: 105-8.
106. Sagi, Y., Weinstock, M., Youdim, M.B.H. *Attenuation of MPTP-Induced Dopaminergic Neurotoxicity by TV3326, A cholinesterase-monoamine oxidase inhibitor*. *J Neurochem* 2003, 2: 290-7.
107. Nishizuka, Y. *The molecular heterogeneity of protein kinase C and its implications for cellular regulation*. *Nature* 1998, 334: 661-5.
108. Montz, H.P., Davis, G.E., Skaper, S.D., Manthorpe, M., Varon, S. *Tumor-promoting phorbol diester mimics two distinct neurotrophic factors*. *Brain Res* 1985, 355: 150-4.
109. Hama, T., Huang, K.P., Guroff, G. *Protein kinase C as a component of a nerve growth factor-sensitive phosphorylation system in PC12 cells*. *Proc Natl Acad Sci USA* 1986, 83: 2353-7.
110. Vianna, M.R., Barros, D.M., Silva, T. et al. *Pharmacological demonstration of the differential involvement of protein kinase C isoforms in short- and long-term memory formation and retrieval of one-trial avoidance in rats*. *Psychopharmacology (Berl)* 2000, 150: 77-84.
111. Jin, L.W., Saitoh, T. *Changes in protein kinases in brain aging and Alzheimer's disease. Implications for drug therapy*. *Drugs Aging* 1995, 6: 136-49.
112. Masliah, E., Cole, G.M., Hansen, L.A. et al. *Protein kinase C alteration is an early biochemical marker in Alzheimer's disease*. *J Neurosci* 1991, 11: 2759-67.
113. Shimohama, S., Narita, M., Matsushima, H., Kimura, J., Kameyama, M., Hagiwara M., Hidaka, H., Taniguchi, T. *Assessment of protein kinase C isozymes by two-site enzyme immunoassay in human brains and changes in Alzheimer's disease*. *Neurology* 1993, 43: 1407-13.
114. Matsushima, H., Shimohama, S., Chachin, M., Taniguchi, T., Kimura, J. *Ca²⁺-dependent and Ca²⁺-independent protein kinase C changes in the brain of patients with Alzheimer's disease*. *J Neurochem* 1996, 67: 317-23.
115. Roth, G.S., Joseph, J.A., Mason, R.P. *Membrane alterations as causes of impaired signal transduction in Alzheimer's disease and aging*. *Trends Neurosci* 1995, 18: 203-6.






116. Wang, H.Y., Pisano, M.R., Friedman, E. *Attenuated protein kinase C activity and translocation in Alzheimer's disease brain*. *Neurobiol Aging* 1994, 15: 293-8.
117. Buxbaum, J.D., Gandy, S.E., Cicchetti, P. et al. *Processing of Alzheimer beta/A4 amyloid precursor protein: Modulation by agents that regulate protein phosphorylation*. *Proc Natl Acad Sci USA* 1990, 87: 6003-6.
118. Nitsch, R.M., Slack, B.E., Wurtman, R.J., Growdon, J.H. *Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors*. *Science* 1992, 258: 304-7.
119. Slack, B.E., Nitsch, R.M., Livneh, E. et al. *Regulation by phorbol esters of amyloid precursor protein release from Swiss 3T3 fibroblasts overexpressing protein kinase C alpha*. *J Biol Chem* 1993, 268: 21097-101.
120. Choeler, F. *Processing of the beta-amyloid precursor protein and its regulation in Alzheimer's disease*. *J Neurochem* 1995, 65: 1431-44.
121. Caputi, A., Barindelli, S., Pastorino, L. et al. *Intracellular secretion of the amino-terminal fragment of amyloid precursor protein in brains of rats with a constitutive up-regulation of protein kinase C*. *J Neurochem* 1997, 68: 2523-9.
122. Rosener, S., Ueberham, U., Yu, J. et al. *In vivo regulation of amyloid precursor protein secretion in rat neocortex by cholinergic activity*. *Eur J Neurosci* 1997, 9: 2125-34.
123. Iln, L., Georgievska, B., Mattsson, A., Isacson, O. *Cognitive changes and modified processing of amyloid precursor protein in the cortical and hippocampal system after cholinergic synapse loss and muscarinic receptor activation*. *Proc Natl Acad Sci USA* 1999, 96: 12108-13.
124. Yogev-Falach, M., Amit, T., Bar-Am, O., Weinstock, M., Youdim, M.B.H. *The involvement of mitogen-activated protein (MAP) kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline*. *FASEB J* 2002, 16: 1674-6.
125. Bar Am, O., Yogev-Falach, M., Amit, T., Sagi, Y., Youdim, M.B. *Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo*. *J Neurochem* 2004b, 89: 1119-25.
126. Ruvolo, P.P., Deng, X., Carr, B.K., May, W.S. *A functional role for mitochondrial protein kinase Calpha in Bcl2 phosphorylation and suppression of apoptosis*. *J Biol Chem* 1998, 273: 25436-42.
127. Guo, B.C., Xu, Y.H. *Bcl-2 over-expression and activation of protein kinase C suppress the trail-induced apoptosis in Jurkat T cells*. *Cell Res* 2001, 11: 101-6.
128. Weinreb, O., Bar-Am, O., Amit, T., Chillag-Talmor, O., Youdim, M.B. *Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members*. *FASEB J* 2004, 18: 1471-3.
129. Kribben, A., Wieder, E.D., Li, X. et al. *AVP-induced activation of MAP kinase in vascular smooth muscle cells is mediated through protein kinase C*. *Am J Physiol* 1993, 265: C939-45.
130. Maher, P. *How protein kinase C activation protects nerve cells from oxidative stress-induced cell death*. *J Neurosci* 2001, 21: 2929-38.
131. Tsujimoto, Y., Shimizu, S. *Bcl-2 family: life-or-death switch*. *FEBS Lett* 2000, 466: 6-10.
132. Aderem, A. *The MARCKS brothers: A family of protein kinase C substrates*. *Cell* 1992, 71: 713-6.
133. Heemskerk, F.M., Chen, H.C., Huang F.L. *Protein kinase C phosphorylates Ser152, Ser156 and Ser163 but not Ser160 of MARCKS in rat brain*. *Biochem Biophys Res Commun* 1993, 190: 236-41.
134. Blackshear, P.J. *The MARCKS family of cellular protein kinase C substrates*. *J Biol Chem* 1993, 268: 1501-4.
135. McNamara, R.K., Lenox, R.H. *Distribution of the protein kinase C substrates MARCKS and MRP in the postnatal developing rat brain*. *J Neurol* 1998, 397: 337-56.
136. McNamara, R.K., Stumpo, D.J., Morel, L.M. et al. *Effect of reduced myristoylated alanine-rich C kinase substrate expression on hippocampal mossy fiber development and spatial learning in mutant mice: Transgenic rescue and interactions with gene background*. *Proc Natl Acad Sci USA* 1998, 95: 14517-22.
137. Saitoh, T., Horsburgh, K., Maslah, E. *Hyperactivation of signal transduction systems in Alzheimer's disease*. *Ann NY Acad Sci* 1993, 695: 34-41.
138. Mochly-Rosen, D. *Localization of protein kinases by anchoring proteins: A theme in signal transduction*. *Science* 1995, 268: 247-51.





139. Battaini, F., Pascale, A., Paoletti, R., Govoni, S. *The role of anchoring protein RACK1 in PKC activation in the ageing rat brain.* Trends Neurosci 1997, 20: 410-5.
140. Battaini, F., Pascale, A., Lucchi, L., Pasinetti, G.M., Govoni, S. *Protein kinase C anchoring deficit in postmortem brains of Alzheimer's disease patients.* Exp Neurol 1999, 159: 559-64.
141. Gasparini, L., Racchi, M., Binetti, G. et al. *Peripheral markers in testing pathophysiological hypotheses and diagnosing Alzheimer's disease.* FASEB J 1998, 12: 17-34.
142. Mills, J., Reiner, P.B. *Regulation of amyloid precursor protein cleavage.* J Neurochem 1999, 72: 443-60.
143. Benussi, L., Govoni, S., Gasparini, L. et al. *Specific role for protein kinase C alpha in the constitutive and regulated secretion of amyloid precursor protein in human skin fibroblasts.* Neurosci Lett 1998, 240: 97-101.
144. Kinouchi T., Sorimachi H., Maruyama K. et al. *Conventional protein kinase C (PKC)-alpha and novel PKC epsilon, but not -delta, increase the secretion of an N-terminal fragment of Alzheimer's disease amyloid precursor protein from PKC cDNA transfected 3Y1 fibroblasts.* FEBS Lett 1995, 364: 203-6.
145. Yeon, S.W., Jung, M.W., Ha, M.J. et al. *Blockade of PKC epsilon activation attenuates phorbol ester-induced increase of alpha-secretase-derived secreted form of amyloid precursor protein.* Biochem Biophys Res Commun 2001, 280: 782-7.
146. Maruyama, W., Nitta, A., Shamoto-Nagai, M. et al. *N-Propargyl-1 (R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-kappaB transcription factor.* Neurochem Int 2004, 44: 393-400.
147. Grilli, M., Memo, M. *Nuclear factor-kappaB/Rel proteins: A point of convergence of signaling pathway relevant in neuronal function and dysfunction.* Biochem Pharmacol 1999, 57: 1-7.
148. Kaltschmidt, B., Uherek, M., Volk, B., Baeuerle, P.A., Kaltschmidt, C. *Transcription factor NF-kappaB is activated in primary neurons by amyloid beta peptides and in neurons surrounding early plaques from patients with Alzheimer disease.* Proc Natl Acad Sci USA 1997, 94: 2642-7.
149. Hunot, S., Brugg, B., Ricard, D. et al. *Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with Parkinson disease.* Proc Natl Acad Sci USA 1997, 94: 7531-6.
150. Qin, Z.H., Wang, Y., Nakai, M., Chase, T.N. *Nuclear factor-kappaB contributes to excitotoxin-induced apoptosis in rat striatum.* Mol Pharmacol 1998, 53: 33-42.
151. Shou, Y., Li, N., Li, L., Borowitz, J.L., Isom, G.F. *NF-kappaB-mediated up-regulation of Bcl-Xs and Bax contributes to cytochrome c release in cyanide-induced apoptosis.* J Neurochem 2002, 81: 842-8.
152. Goodman, Y., Mattson, M.P. *Ceramide protects hippocampal neurons against excitotoxic and oxidative insults, and amyloid beta-peptide toxicity.* J Neurochem 1996, 66: 869-72.
153. Karin, M., Ben-Neriah, Y. *Phosphorylation meets ubiquitination: The control of NF-kappaB activity.* Ann Rev Immunol 2000, 18: 621-63.
154. Weber, C.K., Liptay, S., Wirth, T., Adler, G., Schinid, R.M. *Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of I-kappaB kinases alpha and beta.* Gastroenterology 2000, 119: 1209-18.
155. Kaltschmidt, B., Uherek, M., Wellmann, H., Volk, B., Kaltschmidt, C. *Inhibition of NF-kappaB potentiates amyloid beta-mediated neuronal apoptosis.* Proc Natl Acad Sci USA 1999, 96: 9409-19.
156. Wang, L., Muramatsu, S., Lu, Y. et al. *Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease.* Gene Ther 2002, 9: 381-9.
157. Palfi, S., Leventhal, L., Chu, Y. et al. *Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigro-striatal degeneration.* J Neurosci 2002, 22: 4942-54.
158. Nutt, J.G., Burchiel, K.J., Comella, C.L. et al. *Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD.* Neurology 2003, 14: 69-73.
159. Gill, S.S., Patel, N.K., Hotton, G.R. et al. *Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease.* Nature Med 2003, 9: 589-95.



Mini-Review

Rasagiline: Neurodegeneration, Neuroprotection, and Mitochondrial Permeability Transition

Moussa B.H. Youdim,¹ Orit Bar Am,¹ Merav Yogev-Falach,¹ Orly Weinreb,¹ Wakako Maruyama,² Makato Naoi,² and Tamar Amit¹

¹Eve Topf and USA National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases Research and Department of Pharmacology, and Rappaport Family Research Institute, Technion-Faculty of Medicine, Haifa, Israel

²Department of Neurosciences, Gifu International Institute of Biotechnology, Kakamigahara Gifu, Japan

Mitochondria are involved directly in cell survival and death. The assumption has been made that drugs that protect mitochondrial viability and prevent apoptotic cascade-induced mitochondrial permeability transition pore (MPTp) opening will be cytoprotective. Rasagiline (*N*-propargyl-1*R*-aminoindan) is a novel, highly potent irreversible monoamine oxidase (MAO) B inhibitor anti-Parkinson drug. Unlike selegiline, it is not derived from amphetamine, and is not metabolized to neurotoxic *L*-methamphetamine derivative. In addition, it does not have sympathomimetic activity. Rasagiline is effective as monotherapy or adjunct to levodopa for patients with early and late Parkinson's disease (PD) and adverse events do not occur with greater frequency in subjects receiving rasagiline than in those on placebo. Phase III controlled studies indicate that it might have a disease-modifying effect in PD that may be related to its neuroprotective activity. Its *S* isomer, TVP1022, is more than 1,000 times less potent as an MAO inhibitor. Both drugs, however, have neuroprotective activity in neuronal cell cultures in response to various neurotoxins, and in vivo in response to global ischemia, neurotrauma, head injury, anoxia, etc., indicating that MAO inhibition is not a prerequisite for neuroprotection. Their neuroprotective effect has been demonstrated to be associated directly with the propargylamine moiety, which protects mitochondrial viability and MTPp by activating Bcl-2 and protein kinase C (PKC) and by downregulating the proapoptotic FAS and Bax protein families. Rasagiline and its derivatives also process amyloid precursor protein (APP) to the neuroprotective, neurotrophic, soluble APP α (sAPP α) by PKC- and MAP kinase-dependent activation of α -secretase. The identification of the propargylamine moiety as the neuroprotective component of rasagiline has led us to development of novel bifunctional anti-Alzheimer drugs (ladostigil) possessing cholinesterase and brain-selective MAO inhibitory activity and a

similar neuroprotective mechanism of action.

© 2004 Wiley-Liss, Inc.

Key words: rasagiline; propargyl moiety; Bcl-2 family members; protein kinase C; caspase-3; SHSY5Y neuroblastoma cells

The anti-Parkinson drug (Parkinson Study Group, 2002, 2004), rasagiline (*N*-propargyl-[1*R*]aminoindan) is a potent second-generation monoamine oxidase (MAO) B inhibitor (Youdim et al., 2001a; Finberg and Youdim, 2002). Our studies have provided new insights into the molecular mechanism of neuroprotection induced by rasagiline, its derivatives, and the *N*-propargylamine moiety against a variety of neurotoxins that open the mitochondrial permeability transition pore (MPTp). This involves the Bcl-2 protein family associated with protein kinase C (PKC) pathway activation and interaction with mitochondrial permeability transition (MPT) (Nishizuka, 1988). The latter processes are involved in neuronal survival and functions of neuronal trophic factors (Montz et al., 1985; Hama et al., 1986). They are also critical in formation and consolidation of different types of memory (Vianna et al.,

Contract grant sponsor: Teva Pharmaceutical Company, Haifa, Israel; Contract grant sponsor: National Parkinson Foundation (Miami); Contract grant sponsor: Stein Foundation (Philadelphia); Contract grant sponsor: Rappaport Family Research, Technion-Israel Institute of Technology.

*Correspondence to: Prof. M.B.H. Youdim, Department of Pharmacology, Technion-Faculty of Medicine, PO Box 9697, 31096 Haifa, Israel. E-mail: Youdim@tx.technion.ac.il

Received 6 July 2004; Revised 1 September 2004; Accepted 3 September 2004

Published online 30 November 2004 in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/jnr.20350

2000), suggesting a crucial role for Bcl-2 family proteins and PKC in the aberrant signal transduction occurring in dementia of Alzheimer's disease (AD), Parkinson's disease (PD), and Lewy Body disease (DLB) (Jin and Saitoh, 1995). A deficit in PKC isoform levels in AD and PD (Masliah et al., 1991; Shimohama et al., 1993; Matsushima et al., 1996) is thought to lead to reduced responsiveness of brain tissues to growth factors and neurotransmitters, including acetylcholine and dopamine (Jin and Saitoh, 1995; Roth et al., 1995), and to increased degeneration of neurons. A defect in PKC activation in AD has been documented as a marked loss of redistribution of cytosolic PKC to the particulate fraction in response to phorbol esters and K^+ depolarization in tissue slices from hippocampus, temporal, and frontal cortex (Wang et al., 1994). In vitro and in vivo studies have demonstrated that PKC and PKC-coupled receptors are involved in neuroprotection and in the non-amyloidogenic α -secretase pathway of amyloid precursor protein (APP) processing to the neuroprotective, neurotrophic, soluble amyloid precursor protein α (sAPP α) (Buxbaum et al., 1990; Nitsch et al., 1992; Slack et al., 1993; Caputi et al., 1997; Rossner et al., 1997; Lin et al., 1999; Yogeve-Falach et al., 2002, 2003; Bar-Am et al., 2004a,b). From what has been learned about neuroprotective mechanism of rasagiline, we have thus developed neuroprotective anti-Alzheimer drugs (ladostigil [TV3326] and TV3279) from the pharmacophore of rasagiline. The latter compounds similarly activate antiapoptotic Bcl-2 family proteins and PKCs. Our studies indicate that the mechanism of their neuroprotective activity involves interaction at MPT.

MOLECULAR MECHANISM OF NEUROPROTECTION BY RASAGILINE AND OTHER PROPARGYLAMINES

Accumulating evidence indicates that particular sets of neuronal cells associated with neurodegenerative diseases, such as AD and PD may die of apoptosis (Jellinger, 2000; Yuan and Yankner, 2000), but by no means has this been established fully. Because rasagiline and ladostigil have been developed as drugs possessing possible disease-modifying activity, it was essential to investigate mechanisms underlying the prevention of neuronal cell death. Neuronal cell survival mainly involves activation of PKC-mediated cell viability pathway (Maher, 2001), whereby a classic PKC associates with the Bcl-2 protein family (Ruvolo et al., 1998). The Bcl-2 family proteins are key regulators of the apoptosis program in neurons and may either support cell survival (Bcl-2, Bcl-xL, Bcl-w, Mcl-1, and A1/Bfl-1) or promote cell death (Bax, Bak, Bcl-Xs, Bad, Bid, Bik, Hrk, and Bok) (Tsujimoto and Shimizu, 2000; Cory and Adams, 2002). The members of the Bcl-2 family interact among each other to form a dynamic equilibrium between homo- and heterodimers. Because members of these opposing actions can associate and seemingly titrate each other's function, their relative abundance in a particular cell type may determine the threshold for apoptosis (Oltvai et al., 1993). The competitive action of pro- and anti-survival Bcl-2 family proteins regulates ac-

tivation of the proteases (caspases) that dismantle the cell (Adams and Cory, 1998; Evan and Littlewood, 1998; Zamzami et al., 1998).

Rasagiline (Youdim et al., 2001a; Parkinson Study Group 2002, 2004) has broad neuroprotective activity against a variety of neurotoxins in neuronal cell cultures (Finberg et al., 1998; Maruyama et al., 2001b,c; Youdim et al., 2001b, 2003) and in animal models of closed head trauma (Huang et al., 1999), global and focal ischemia (Speiser et al., 1999) and *N*-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-(MPTP)-induced neurotoxicity (Sagi et al., 2001, 2003) and transgenic mouse model of amyotrophic lateral sclerosis (Waibel et al., 2004) and 6-hydroxydopamine model of Parkinson's disease in rat (Blandini et al., 2004). The molecular mechanism of neuroprotection by rasagiline has been studied in SHSY5Y and PC12 cells in culture against apoptosis induced by *N*-methyl-*R*-salsolinol, the peroxynitrite donor SIN-1, and 6-hydroxydopamine. It has also been studied in serum and nerve growth factor (NGF) withdrawal (Naoi and Maruyama, 2001; Youdim and Weinstock, 2001; Youdim, 2003). The demonstration that its optical *S* isomer, TVP1002, which is 1,000 times less active as an MAO inhibitor, has a similar neuroprotective activity (Maruyama et al., 2000; Youdim et al., 2001b) indicates that the neuroprotective activity of rasagiline and other propargylamines are not dependent on their MAO inhibitory activity.

Rasagiline and its related propargylamines suppress the apoptotic cell death cascade initiated by mitochondria (Youdim et al., 2001b; Akao et al., 2002b). In response to neurotoxins (SIN-1 or *N*-methyl-*R*-salsolinol), they prevent preapoptotic swelling of mitochondria and the decline in mitochondrial membrane potential ($\Delta\Psi_m$) resulting from permeability transition. They also prevent the following apoptotic processes: activation of caspase 3; activation of nuclear PARP-1; translocation of glyceraldehyde-3-phosphate dehydrogenase (GADPH); and nucleosomal DNA fragmentation (Youdim and Weinstock, 2001; Youdim, 2003; Bar-Am et al., 2004a,b; Weinreb et al., 2004). In addition, rasagiline increases expression of anti-apoptotic Bcl-2 and Bcl-xL and downregulates pro-apoptotic Bad and Bax in SHSY5Y cells (2001a; Youdim, 2003; Yogeve-Falach et al., 2003; Bar-Am et al., 2004a,b).

RASAGILINE AND MPT

Mitochondria play a critical role in and are potent integrators and coordinators of cell death (apoptosis and necrosis) and survival. Apoptosis and necrosis are modes of cell death that play an integral part in many biological processes and their demise have been implicated in a variety of neurodegenerative and nonneurodegenerative diseases such as cardiovascular disease and diabetes (see for reviews Suleiman et al., 2001; Belzacq et al., 2002; Halestrap et al., 2002; Belzacq and Brenner, 2003). The participation of mitochondrial-induced apoptosis in neuronal cell death has not been established fully and remains a controversial subject. Nevertheless, it has been a target for study of neurotoxin-induced cell death and neuroprotection in progressive loss of neurons and cytoprotection in cardiovascular diseases with a variety of pharmacologic

agents. The initial phase of apoptosis is triggered in response to an induction phase resulting from a variety of insults, such as xenobiotics, Parkinsonism-endogenous (*N*-methyl-*R*-salsolinol) and exogenous (6-hydroxydopamine and MPTP) neurotoxins, radiation, oxidative stress, and glucose and oxygen deprivation. This is accompanied by a change in mitochondrial membrane permeability (MMP) that results in opening of the MPTp complex, a nonspecific pore, under conditions of elevated matrix Ca^{2+} , oxidative stress, and depletion of adenine nucleotides. MPTp opening causes a massive swelling of mitochondria and a decline in mitochondrial membrane potential ($\Delta\Psi_m$) resulting from the rupture of the outer membrane. This, followed by inhibition of ubiquitin-proteasome complex, release of mitochondrial cytochrome *c*, and activation of caspases (especially caspase 3) and PARP-1, results in cell death by apoptosis (Belzacq et al., 2002, 2003; Halestrap et al., 2002). MPTp plays a central role in induction and prevention of apoptosis-induced cell death and consists of a mitochondrial multi-protein complex that includes porin, hexokinase, peripheral benzodiazepine receptor, creatine kinase, adenosine nucleotide translocase, and cyclophilin D; however, its exact nature is not yet known.

The direct involvement of MPTp in apoptotic-induced death of mammalian cells including neurons in cell culture and in vivo in variety of models has been well documented (Youdim, 2003). The important role of MPTp is also supported by the findings that the MPTp complex, particularly the voltage-dependent anion channel (VDAC) and adenosine nucleotide translocase (ANT), are direct functional targets for Bcl-2 family proteins. Mitochondrial phase function is controlled by oncogenes and antioncogenes of the Bcl-2-Bax family. Antiapoptotic members (Bcl-2, Bcl-xL, etc.) stabilize MPTp, whereas proapoptotic members (Bax, Bak, Bad, and Bid) promote and increase in MPP (see for reviews Suleiman et al., 2001; Belzacq et al., 2002, 2003; Halestrap et al., 2002; Belzacq and Brenner, 2003). For example, we have shown that in response to the endogenous dopaminergic neurotoxin *N*-methyl-*R*-salsolinol in the integration phase, there occurs in neuroblastoma SHSY5Y cell mitochondria a loss of $\Delta\Psi_m$, swelling of mitochondria matrix; oxidative stress, and opening of MPP, whereas pretreatment of the cells with rasagiline prevents these responses (Akao et al., 2002a,b). In addition, rasagiline prevents inhibition of the ubiquitin-proteasome system by the neurotoxin that results in release of toxic intermembrane proteins such as cytochrome *c*. These are followed by a complex set of events, which includes activation of procaspases and caspase 3, resulting in nuclear chromatin condensation, DNA fragmentation and change in plasma membrane that culminates in neuron death (Akao et al., 2002a,b).

In structural activity studies, we investigated the mechanism underlying the relation between Bcl-2 family members and PKC signaling in neuroprotection and MPT to determine the molecular structure responsible for neuroprotective activities of rasagiline and its bifunctional




Fig. 1. Schematic representation of the mechanism of neuroprotective action of rasagiline that is also shared by ladostigil (TV3326) and *N*-propargylamine. These propargylamines activate PKC α and ϵ but downregulate δ and γ . In this respect, they behave opposite to proapoptotic drugs. They also activate ERK1/2 phosphorylation, which together with PKC have been shown to be responsible for the neuroprotective activities because PKC and ERK inhibitors prevent cell survival activity via activation of antiapoptotic Bcl-2 family proteins and downregulation of caspase 3 and cleaved PARP. At least rasagiline has also been shown to induce BDNF and GDNF and release of the latter. This may account for the neuroprotective and possible neurorescue activity of these drugs (Yogev-Falach et al., 2002, 2003; Youdim, 2003; Bar-Am et al., 2004; Maruyama et al., 2004; Weinreb et al., 2004).

derivative ladostigil (TV3326). Rasagiline-induced neuroprotection exhibited in response to the neurotoxin *N*-methyl-*R*-salsolinol is seen also with other neurotoxic events and compounds (e.g., SIN-1, glutamate, and A β amyloid) that induce neuronal death (Maruyama et al., 2000; Maruyama et al., 2001a,b; Yogev-Falach et al., 2003; Weinreb et al., 2004). This has provided the first evidence that propargylamines and rasagiline antiapoptotic drugs regulate the anti- and proapoptotic signaling pathways in mitochondria (Youdim, 2003). The ability of rasagiline to inhibit *N*-methyl-*R*-salsolinol-induced collapse of $\Delta\Psi_m$, swelling of mitochondria, and MPP opening in the SHSY5Y cells is associated with activation of antiapoptotic Bcl-2 family proteins Bcl-2 and Bcl-xL and downregulation of Bad and Bax (Akao et al., 2002a,b; Weinreb et al., 2004). Evidence for this has come from the studies demonstrating that rasagiline increases Bcl-2 and Bcl-xL mRNA and protein (Fig. 1) but decreases Bax and Bad mRNA and protein in SHSY5Y and PC12 cells. In this regard, Bcl-2-overexpressing SHSY5Y cells behave identical to those treated by rasagiline in that they are resistant to neurotoxicity initiated by *N*-methyl-*R*-salsolinol, SIN-1 and 6-hydroxydopamine. Inhibition of ubiquitin-proteasome system by *N*-methyl-*R*-salsolinol, which re-

sults in cryptozotic translocation of GAPDH and activation of cytochrome c oxidase by the cytochrome c release, is also prevented by pretreatment with rasagiline. A similar result is also obtained with SHSY5Y cells overexpressing Bcl-2. Further support for Bcl-2 family protein participation in the neuroprotective activity of rasagiline has come from cDNA microarray gene expression and proteomic profiling in mouse midbrain resulting from chronic rasagiline treatment, where cell survival- (Bcl-2 and Bcl-xL) and death (Bax and Bad)-inducing family proteins are up- and downregulated, respectively (Sagi et al., 2003).

Structure-activity relationship studies with rasagiline and ladostigil and their non-MAO inhibitor *S* isomer derivatives (TVP1022 and TV3279) have indicated that the propargyl moiety in these drugs is crucial for the neuroprotective activity (Maruyama et al., 2003; Yogev-Falach et al., 2003). Their aminoindan metabolite is not antiapoptotic, however, and only in certain conditions does it have neuroprotective activity, as in the case of serum withdrawal in partially neuronally differentiated PC12 cells (Maruyama et al., 2003; Bar-Am et al., 2004a). The mechanism of neuroprotective action of rasagiline and its derivatives in some respects resembles that of cyclosporine A, which has been shown to be cardioprotective in heart myocytes and neuroprotective against a variety of neurotoxins, including *N*-methyl-*R*-salsolinol, SIN-1, and MPTP. Unlike cyclosporine A, however, rasagiline is unable to fully suppress the Ca²⁺-induced MPP opening, as is seen with Bcl-2 overexpression and the action of bonkrekic A, which target respective components of the MPTp complex (Akao et al., 2002a,b). Nevertheless, in many respects the neuroprotective response of SHSY5Y cells to rasagiline is very similar to that of cells overexpressing Bcl-2 (Maruyama et al., 2001a, Akao et al., 2002). Such cells are also resistant to apoptosis by neurotoxins such as *N*-methyl-*R*-salsolinol, in which there is no collapse of $\Delta\Psi_m$, inhibition of ubiquitin-proteasome system, release of cytochrome c, or GAPDH translocation from cytoplasm to the nucleus in response to the neurotoxin (Maruyama et al., 2001a; Akao et al., 2002a,b). Our present studies are directed at identifying upstream target protein(s) and at which VDAC protein site rasagiline acts upon in the mitochondria (Maruyama et al., 2001a,b).

LADOSTIGIL, A NOVEL ANTI-ALZHEIMER BIFUNCTIONAL CHOLINESTERASE-MAO INHIBITOR DERIVATIVE OF RASAGILINE

We have synthesized recently a series of novel propargylamine bifunctional drugs with a carbamate cholinesterase (ChE) inhibitory moiety in the pharmacophore of rasagiline to preserve its neuroprotective activity and inhibit MAO and acetyl ChE to increase dopaminergic and cholinergic transmissions (Weinstock et al., 2001). The *R* enantiomer of these compounds, ladostigil (TV3326, [(*N*-propargyl-[3*R*]aminoindan-5-yl)-ethyl methyl carbamate]), inhibits butyrylcholinesterase and ChE for a longer time than rivastigmine does, with a greater affinity for the former and a selective inhibitor for brain MAO-AB. It im-

proves memory impairment in scopolamine-treated rats. Its *S* isomer, TV3279, is also a ChE inhibitor but has no MAO inhibitory activity, and has similar action in the scopolamine impairment test (Weinstock et al., 2000, 2001). As an MAO-AB inhibitor, it has anti-Parkinson activity in the MPTP mouse model (Sagi et al., 2003) and antidepressant activity in the forced swim test, because it raises brain levels of dopamine, serotonin, and noradrenaline (Weinstock et al., 2002, 2003; Sagi et al., 2003). These compounds retain the neuroprotective activities of rasagiline in response to various neurotoxins in partially differentiated PC12 and SHSY5Y neuroblastoma cells deprived of serum and NGF and in vivo (Weinstock et al., 2000, 2003; Youdim et al., 2001b). TV3326 (ladostigil) and TV3279, which possess the propargylamine moiety of rasagiline, share the same neuroprotective property and mechanism of action of the parent drug (Maruyama et al., 2003).

RASAGILINE, PKC, AND NEUROPROTECTION

PC12 and SHSY5Y neuroblastoma cell viability is reduced markedly by 24-hr serum withdrawal ($75.8 \pm 6\%$ and $73.2 \pm 7\%$ of full-serum control, respectively). Rasagiline significantly prevents cell death induced by serum deprivation in PC12 and SHSY5Y neuroblastoma cells. Consistent with its antiapoptotic activity, rasagiline is able to prevent the appearance of the cleaved activated form of caspase-3 and the cleavage of the caspase substrate, PARP-1. This is PKC dependent, because the specific broad-spectrum PKC inhibitor GF109203X, which exhibits high affinity for conventional PKCs (α , β , and γ) as well as the novel isoenzyme PKC ϵ (Ku et al., 1997; Gekeler et al., 1996) prevents this and the neuroprotective activity. Moreover, rasagiline decreases serum free-induced cleavage and activation of caspase-3 and PARP-1 and the increase in Bad and Bax that occurs in serum-free PC12 and SHSY5Y cells. These effects are prevented by the PKC inhibitor GF109203X and the MEK inhibitor PD98056 ET. These studies indicate the involvement of the PKC-MAP kinase-dependent pathway in rasagiline-stimulated cell viability and survival. The activation of PKC is associated with protection of neuronal cells (Durkin et al., 1997; Maher, 2001). Short-term treatment of PC12 cells with rasagiline dose-dependently induces significant PKC phosphorylation, which is inhibited by GF109203X (Weinreb et al., 2004). PKC translocation to the membrane fraction upon activation and membrane localization is used often as a marker for PKC activation. PMA is known to markedly induce translocation of p-PKC (pan), PKC α , and PKC ϵ in PC12 cells (Wooten et al., 1994). Rasagiline has a similar activating effect on p-PKC, PKC α , and PKC ϵ translocation to the membrane fractions. These results are supported by previous studies in which we have shown that rasagiline treatment activates PKC and its isoforms in rat and mouse hippocampus (Bar-Am et al., 2004a) and causes its translocation (Weinreb et al., 2004).

N-PROPARGYLAMINE AS THE NEUROPROTECTIVE MOIETY OF RASAGILINE AND LADOSTIGIL

Although structural activity studies with propargylamines have shown that the propargyl moiety may be responsible for the neuroprotective activity, *N*-propargylamine itself has been studied only recently (Weinreb et al., 2004). We have shown recently that *N*-propargylamine at low concentrations (1 and 10 μ M) significantly reduces cell death induced by serum deprivation in PC12 and SHSY5Y neuroblastoma cells, with a concomitant decrease in activated caspase-3 and PARP. Moreover, treatment of PC12 cells with increasing concentrations of *N*-propargylamine results in a significant, dose-dependent increase in PKC phosphorylation; pretreatment with GF109203X and PD blocks the effect of propargylamine on PKC phosphorylation. Real-time RT-PCR analysis revealed that 24-hr treatment of PC12 cells with *N*-propargylamine significantly increased Bcl-xL and Bcl-w mRNA expression and decreased Bad and Bax mRNA expression, compared to the levels observed in serum-free cultures (Weinreb et al., 2004). In addition, similar to rasagiline and ladostigil, *N*-propargylamine increased PKC α and PKC ϵ mRNA levels and reduced PKC γ mRNA levels compared to those detected in serum-free culture (Bar-Am et al., 2004a,b; Weinreb et al., 2004).

GENOMIC AND PROTEOMIC PROFILING OF RASAGILINE AND *N*-PROPARGYLAMINE NEUROPROTECTIVE ACTIVITY

To determine further the mechanism of rasagiline and *N*-propargylamine-neuroprotection, we carried out in cultured PC12 cells customized cDNA microarray gene expression changes in cell-survival and death-related genes, including selected Bcl-2 and PKC family members (Weinreb et al., 2004). Real-time RT-PCR consisted of RNA samples isolated from PC12 cells, maintained in full-serum or serum-free media and treated with or without rasagiline (0.01–10 μ M) for 24 hr. Expression of each gene was normalized to the housekeeping gene 18S rRNA, because this transcript is reportedly less susceptible to influence by external factors (Schmittgen and Zakrajsek, 2000). Real-time RT-PCR demonstrated that in serum-free culture, Bcl-2, Bcl-w, and Bcl-xL expression levels were reduced significantly (~60% of that in full-serum culture), whereas Bad and Bax mRNA levels were increased markedly (~1.8- and ~2.5-fold, respectively, vs. full-serum culture). Rasagiline treatment for 24 hr significantly induced Bcl-xL and Bcl-w mRNA expression (at 1 μ M, by ~2- and ~1.35-fold, respectively, vs. serum-free culture). In addition, rasagiline markedly reduced mRNA of Bad and Bax expression (at 1 μ M, ~70% of that in serum-free culture).

Examination of the effect of rasagiline on PKC gene expression by real-time RT-PCR analysis using RT primers specific for PKC α , PKC ϵ , PKC δ and PKC γ revealed

that in serum-free PC12 culture, PKC α and PKC ϵ mRNA expression levels are reduced significantly whereas PKC δ and PKC γ mRNA levels were increased markedly. Treatment of serum-free PC12 cells with rasagiline (1 and 10 μ M) for 24 hr upregulated PKC α and PKC ϵ mRNA levels, compared to the decreased expression detected in serum-free culture. In addition, rasagiline downregulated the increased PKC γ mRNA level observed in serum-deprived cells. Moreover, quantitative real-time RT-PCR pointed to an association between the mechanism of rasagiline neuroprotective action and brain-derived neurotrophic factor (BDNF) gene expression. BDNF gene expression downregulation occurring in serum-deprived PC12 cells are reversed by treatment with 1 and 10 μ M of rasagiline with a 3.5-fold increase in BDNF (Weinreb et al., 2004). The ability of rasagiline to increase BDNF mRNA (Weinreb et al., 2004) and induce the release of glia cell line-derived neurotrophic factor (GDNF) in SHSY5Y cells (Maruyama et al., 2004) may point to its neurorescue via activation of neurotrophic cell surface receptors. Almost identical results have been obtained with *N*-propargylamine (Weinreb et al., 2004).

DISCUSSION

Our studies have demonstrated clearly that the neuroprotective activity of rasagiline and its derivatives is associated with the propargyl moiety in these drugs. These compounds activate the Bcl-2 antiapoptotic family proteins Bcl-2 and Bcl-xL and downregulate proapoptotic Bad and Bax. Given that the antiapoptotic activity of rasagiline and *N*-propargylamine in serum-free cells is blocked by PKC and MEK inhibitors clearly supports a role for PKC and MEK involvement in their neuroprotective mechanisms. (Fig. 1). These findings are complementary in activation of PKC α and PKC ϵ in serum-deprived PC12 cells, the isoforms essentially involved in cell survival pathways. Furthermore, real-time PCR analyses have revealed that exposure of serum-deprived PC12 cells to rasagiline and *N*-propargylamine markedly increases PKC α and PKC ϵ gene expression but decreases elevated PKC γ mRNA levels. Previous studies showed that that PKC γ was increased in ischemia (Selvatici et al., 2003), in which rasagiline is protective (Speiser et al., 1999) and decreased by the immunosuppressant cerebroprotective agent FK506 (Katsura et al., 2003).

Certain PKC isoforms are thought to act to deliver survival signals that protect against cell death. For instance, PKC α was shown to phosphorylate Bcl-2 at a site that increases its antiapoptotic function (Ruvolo et al., 1998), whereas overexpression of PKC ϵ results in increased expression of Bcl-2. Suppression of PKC α triggers apoptosis through downregulation of Bcl-xL (Hsieh et al., 2003). In addition, MAPK/ERK cascades, which have been shown to inhibit cell death in a number of systems, can be activated by PKC. PKC α thus phosphorylates and activates Raf-1, an upstream kinase in the MAPK/ERK pathway (Kribben et al., 1993). Indeed our proteomic analysis has shown clearly that in vivo rasagiline upregulates Ras, Raf-1, PI3K, and AKT (Sagi et al., 2003). PKC ϵ regulates

ERK-1 and -2 activation; and pharmacologic inhibition of MAPK/ERK signaling blocks phorbol ester-induced protection of neuronal cells against glutamate toxicity (Maher, 2001). These findings explain the activation of the MAPK/ERK cascade by rasagiline, ladostigil, and *N*-propargylamine (Yogev-Falach et al., 2002, 2003). The involvement of PKC pathway in rasagiline and *N*-propargylamine-induced inactivation of the proapoptotic Bcl-2 family members, Bad and Bax, is consistent with PKC-dependent pathway promoting cell survival via phosphorylation and inactivation of Bad-mediated cell death (Tan et al., 1999).

Proteomic analysis of midbrain of mice treated in vivo with rasagiline alone or its prevention of parkinsonian syndrome in MPTP-induced nigrostriatal dopamine neuron death have demonstrated that this drug has complex mechanism of neuroprotective activity that involves several cascades. These include activation of PKC-MAP kinase pathways identified with cultured PC12 and SHSY5Y cells (Weinreb et al., 2004; Bar-Am et al., 2004b), the neurotrophic factors GDNF, BDNF, and NGF and the PI3K-AKT pathway via upregulation of Ras (Sagi et al., 2003; Maruyama et al., 2004; Weinreb et al., 2004) and downregulation of Fas and Fas ligand, which interact with Bad and Bax on the outer mitochondrial membrane (Sagi et al., 2003).

Rasagiline increases the expression of BDNF, GDNF, and NGF (Fig. 1), neurotrophins found to promote survival of all major neuronal types affected in AD and PD animal models (Murer et al., 2001). Reduced BDNF expression was demonstrated in the substantia nigra of individuals with PD (Parain et al., 1999) and BDNF prevented spontaneous death of dopaminergic neurons in rat primary mesencephalic culture (Hyman et al., 1991) and the reduction in striatal dopamine content induced by MPTP in mice (Huang et al., 1999). Interestingly, BDNF was also reported to regulate PKC activation (Tremblay et al., 1999) and affect Bcl-w and Bcl-xL expression (Middleton et al., 2001). Moreover, rasagiline was reported recently in SHSY5Y cells to increase expression and release of GDNF (Maruyama et al., 2004), another neurotrophic factor that may have specificity for dopamine neurons. Recent clinical studies with a central infusion of this factor in PD subjects have shown partial recovery from PD. The ability of rasagiline to activate antioxidant enzymes superoxide dismutase (SOD) and catalase (Carrillo et al., 2000) suggests that these, together with its action on Bcl-2 family protein and PKCs, can suppress the death process and promote survival of dopamine neurons (Fig. 1) (Maruyama et al., 2004). These results may explain those of recent controlled studies with rasagiline in PD in which the decline in disability could not be explained by the symptomatic effect of the drug but may have been due to a disease-modifying activity of rasagiline (Parkinson Study Group, 2004). Further study will clarify the interrelationship between rasagiline-induced BDNF, GDNF, or other neurotrophic substances, PKC signaling pathway, Bcl-2-related protein

family, and neuroprotection in our animal studies and its possible disease modifying activity not only in PD subjects but also in AD.

REFERENCES

- Adams JM, Cory S. 1998. The Bcl-2 protein family: arbiters of cell survival. *Science* 281:1322-1326.
- Akao Y, Maruyama W, Yi H, Shamoto-Nagai M, Youdim MBH, Naoi M. 2002a. An anti-Parkinson's disease drug, *N*-propargyl-1(*R*)-aminoindan (rasagiline), enhances expression of anti-apoptotic Bcl-2 in human dopaminergic SH-SY5Y cells. *Neurosci Lett* 326:105-108.
- Akao Y, Maruyama W, Shimizu S, Yi H, Nakagawa Y, Shamoto-Nagai M, Youdim MB, Tsujimoto Y, Naoi M. 2002b. Mitochondrial permeability transition mediates apoptosis induced by *N*-methyl(*R*)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, *N*-propargyl-1(*R*)-aminoindan. *J Neurochem* 82:913-923.
- Bar-Am OB, Amit T, Youdim MB. 2004a. Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. *Neurosci Lett* 355:169-172.
- Bar-Am O, Yogev-Falach M, Amit T, Sagi Y, Youdim MB. 2004b. Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo. *J Neurochem* 89:1119-1125.
- Belzacq AS, Brenner C. 2003. The adenine nucleotide translocator: a new potential chemotherapeutic target. *Curr Drug Targets* 7:517-524.
- Belzacq AS, Vieira HL, Kroemer G, Brenner C. 2002. The adenine nucleotide translocator in apoptosis. *Biochimie* 84:167-176.
- Belzacq AS, Vieira HL, Verrier F, Vandecasteele G, Cohen I, Prevost MC, Larquet E, Pariselli F, Petit PX, Kahn A, Rizzuto R, Brenner C, Kroemer G. 2003. Bcl-2 and Bax modulate adenine nucleotide translocase activity. *Cancer Res* 63:541-546.
- Blandini F, Armentero MT, Fancelli R, Blaugrund E, Nappi G. 2004. Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease. *Exp Neurol* 187:455-459.
- Buxbaum JD, Gandy SE, Cicchetti P, Ehrlich ME, Czernik AJ, Fracasso RP, Ramabhadran TV, Unterbeck AJ, Greengard P. 1990. Processing of Alzheimer beta/A4 amyloid precursor protein: modulation by agents that regulate protein phosphorylation. *Proc Natl Acad Sci USA* 87:6003-6006.
- Caputi A, Barindelli S, Pastorino L, Cimino M, Buxbaum JD, Cattabeni F, Di Luca M. 1997. Increased secretion of the amino-terminal fragment of amyloid precursor protein in brains of rats with a constitutive up-regulation of protein kinase C. *J Neurochem* 68:2523-2529.
- Carrillo MC, Minami C, Kitani K, Maruyama W, Ohashi K, Yamamoto T, Naoi M, Kanai S, Youdim MB. 2000. Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the rat. *Life Sci* 67:577-585.
- Cory S, Adams JM. 2002. The Bcl2 family: regulator of the cellular life-or-death switch. *Nat Rev Cancer* 2:647-656.
- Durkin JP, Tremblay R, Chakravarthy B, Mealing G, Morley P, Small D, Song D. 1997. Evidence that the early loss of membrane protein kinase C is a necessary step in the excitatory amino acid-induced death of primary cortical neurons. *J Neurochem* 68:1400-1412.
- Evan G, Littlewood T. 1998. A matter of life and cell death. *Science* 28:1317-1322.
- Finberg JP, Takeshima T, Johnston JM, Commissiong JW. 1998. Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor. *Neuroreport* 9:703-707.
- Finberg JP, Youdim MB. 2002. Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours. *Neuropharmacology* 43:1110-1118.
- Halestrap AP, McStay GP, Clarke SJ. 2002. The permeability transition pore complex: another view. *Biochimie* 84:153-166.

- Hama T, Huang KP, Guroff G. 1986. Protein kinase C as a component of a nerve growth factor-sensitive phosphorylation system in PC12 cells. *Proc Natl Acad Sci USA* 83:2353-2357.
- Hsieh YC, Jao HC, Yang RC, Hsu HK, Hsu C. 2003. Suppression of protein kinase C α triggers apoptosis through down-regulation of Bcl-xL in a rat hepatic epithelial cell line. *Shock* 19:582-587.
- Huang W, Chen Y, Shohami E, Weinstock M. 1999. Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse. *Eur J Pharmacol* 366:127-135.
- Hyman C, Hofer M, Barde YA, Juhasz M, Yancopoulos GD, Squinto SP, Lindsay RM. 1991. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. *Nature* 350:230-232.
- Jellinger KA. 2000. Cell death mechanisms in Parkinson's disease. *J Neural Transm* 107:1-29.
- Jin LW, Saitoh T. 1995. Changes in protein kinases in brain aging and Alzheimer's disease. Implications for drug therapy. *Drugs Aging* 6:136-149.
- Katsura K, Kurihara J, Hiraide T, Takahashi K, Kato H, Katayama Y. 2003. Effects of FK506 on the translocation of protein kinase C and CaM kinase II in the gerbil hippocampal CA1 neurons. *Neurol Res* 25:522-527.
- Kribben A, Wieder ED, Li X, van Putten V, Granot Y, Schrier RW, Nemenoff RA. 1993. AVP-induced activation of MAP kinase in vascular smooth muscle cells is mediated through protein kinase C. *Am J Physiol* 265:939-945.
- Lin L, Georgievska B, Mattsson A, Isacson O. 1999. Cognitive changes and modified processing of amyloid precursor protein in the cortical and hippocampal system after cholinergic synapse loss and muscarinic receptor activation. *Proc Natl Acad Sci USA* 96:12108-12113.
- Maher P. 2001. How protein kinase C activation protects nerve cells from oxidative stress-induced cell death. *J Neurosci* 21:2929-2938.
- Maruyama W, Akao Y, Youdim MB, Naoi M. 2000. Neurotoxins induce apoptosis in dopamine neurons: protection by *N*-propargylamine-1(*R*)- and (*S*)-aminoindan, rasagiline and TV1022. *J Neural Transm Suppl* 60:171-186.
- Maruyama W, Akao Y, Youdim MB, Boulton AA, Davis BA, Naoi M. 2001b. Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3 phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, *N*-methyl(*R*)salsolinol. *J Neurochem* 78:727-735.
- Maruyama W, Boulton AA, Davis BA, Dostert P, Naoi M. 2001a. Enantio-specific induction of apoptosis by an endogenous neurotoxin, *N*-methyl(*R*)salsolinol, in dopaminergic SH-SY5Y cells: suppression of apoptosis by *N*-(2-heptyl)-*N*-methylpropargylamine. *J Neural Transm* 108: 11-24.
- Maruyama W, Nitta A, Shamoto-Nagai M, Hirata Y, Akao Y, Youdim M, Furukawa S, Nabeshima T, Naoi M. 2004. *N*-Propargyl-1 (*R*)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-kappaB transcription factor. *Neurochem Int* 44:393-400.
- Maruyama W, Weinstock M, Youdim MB, Nagai M, Naoi M. 2003. Anti-apoptotic action of anti-Alzheimer drug, TV3326 [(*N*-propargyl)-(3*R*)-aminoindan-5-yl]-ethyl methyl carbamate, a novel cholinesterase-monoamine oxidase inhibitor. *Neurosci Lett* 8:233-236.
- Maruyama W, Youdim MB, Naoi M. 2001c. Antiapoptotic function of *N*-propargylamine-1(*R*)- and (*S*)-aminoindan, rasagiline, and TV1022. *Ann N Y Acad Sci* 939:320-329.
- Masliah E, Cole GM, Hansen LA, Mallory M, Albright T, Terry RD, Saitoh T. 1991. Protein kinase C alteration is an early biochemical marker in Alzheimer's disease. *J Neurosci* 11:2759-2767.
- Matsushima H, Shimohama S, Chachin M, Taniguchi T, Kimura J. 1996. Ca²⁺-dependent and Ca²⁺-independent protein kinase C changes in the brain of patients with Alzheimer's disease. *J Neurochem* 67:317-323.
- Middleton, G, Wyatt S, Nikiman N, Davies M, Nabeshima T. 2001. Reciprocal developmental changes in the roles of Bcl-w and Bcl-x(L) in regulating sensory neuron survival. *Development* 128:447-457.
- Montz HP, Davis GE, Skaper SD, Manthorpe M, Varon S. 1985. Tumor-promoting phorbol diester mimics two distinct neurotrophic factors. *Brain Res* 355:150-154.
- Murer MG, Yan Q, Raisman-Vozari R. 2001. Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease. *Prog Neurobiol* 63:71-124.
- Naoi M, Maruyama W. 2001. Future of neuroprotection in Parkinson's disease. *Parkinsonism Relat Disord* 8:139-145.
- Nishizuka Y. 1988. The molecular heterogeneity of protein kinase C and its implications for cellular regulation. *Nature* 334:661-665.
- Nitsch RM, Slack BE, Wurtman RJ, Growdon JH. 1992. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. *Science* 258:304-307.
- Oltvai ZN, Millman CL, Korsmeyer SJ. 1993. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. *Cell* 74:609-619.
- Parain K, Murer MG, Yan O, Faucheux B, Agid Y, Hirsch E, Raisman Vozari R. 1999. Reduced expression of brain-derived neurotrophic factor protein in Parkinson's disease substantia nigra. *Neuroreport* 10:557-561.
- Parkinson Study Group. 2002. A controlled trial of rasagiline in early Parkinson disease. *Arch Neurol* 59:1937-1993.
- Parkinson Study Group. 2004. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. *Arch Neurol* 61:561-566.
- Rosner S, Ueberham U, Yu J, Kirazov L, Schliebs R, Perez-Polo JR, Bigl V. 1997. In vivo regulation of amyloid precursor protein secretion in rat neocortex by cholinergic activity. *Eur Neurosci* 9:2125-2134.
- Roth GS, Joseph JA, Mason RP. 1995. Membrane alterations as causes of impaired signal transduction in Alzheimer's disease and aging. *Trends Neurosci* 18:203-206.
- Ruvolo PP, Deng X, Carr BK, May WS. 1998. A functional role for mitochondrial protein kinase C alpha in Bcl2 phosphorylation and suppression of apoptosis. *J Biol Chem* 273:25436-25442.
- Sagi Y, Weinreb O, Weinstock M, Youdim MB. 2001. Neuroprotective and neurorescue properties of rasagiline and TV3326 in MPTP model of Parkinson's disease. *Neural Plast* 8:197-198.
- Sagi Y, Weinstock M, Youdim MB. 2003. Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor. *J Neurochem* 85:290-297.
- Schmittgen TD, Zakrajsek BA. 2000. Effect of experimental treatment on housekeeping gene expression: validation by real-time, quantitative RT-PCR. *J Biochem Biophys Methods* 46:69-81.
- Selvatici R, Marino S, Piubello C, Radi D, Beani C, Gardini E, Siniscalchi A. 2003. Protein kinase C activity, translocation, and selective isoform subcellular redistribution in the rat cerebral cortex after in vitro ischemia. *J Neurosci Res* 71:64-71.
- Shimohama S, Narita M, Matsushima H, Kimura J, Kameyama M, Hagiwara M, Hidaka H, Taniguchi T. 1993. Assessment of protein kinase C isozymes by two-site enzyme immunoassay in human brains and changes in Alzheimer's disease. *Neurology* 43:1407-1413.
- Slack BE, Nitsch RM, Livneh E, Kunz GM Jr, Breu J, Eldar H, Wurtman RJ. 1993. Regulation by phorbol esters of amyloid precursor protein release from Swiss 3T3 fibroblasts over expressing protein kinase C alpha. *J Biol Chem* 268:21097-21101.
- Tsujimoto Y, Shimizu S. 2000. Bcl-2 family: life-or-death switch. *FEBS Lett* 466:6-10.
- Speiser Z, Mayk A, Eliash S, Cohen S. 1999. Studies with rasagiline, a MAO-B inhibitor, in experimental focal ischemia in the rat. *J Neural Transm* 106:593-606.
- Suleiman MS, Halestrap AP, Griffiths EJ. 2001. Mitochondria: a target for myocardial protection. *Pharmacol Ther* 89:29-46.
- Tan Y, Ruan HD, Comb MJ. 1999. p90(RSK) blocks bad-mediated cell death via a protein kinase C-dependent pathway. *J Biol Chem* 274: 34859-34867.

- Tremblay R, Hewitt K, Lesiuk H, Mealing G, Morley P, Durkin JP. 1999. Evidence that brain-derived neurotrophic factor neuroprotection is linked to its ability to reverse the NMDA-induced inactivation of protein kinase C in cortical neurons. *J Neurochem* 72:102-111.
- Vianna MR, Barros DM, Silva T, Choi H, Madche C, Rodrigues C, Medina JH, Izquierdo I. 2000. Pharmacological demonstration of the differential involvement of protein kinase C isoforms in short- and long-term memory formation and retrieval of one-trial avoidance in rats. *Psychopharmacology* 150:77-84.
- Waibel S, Reuter A, Malessa S, Blaugrund E, Ludolph AC. 2004. Rasagiline alone and in combination with rituzole prolongs survival in ALS mouse model. *J Neurol* 251:1080-1084.
- Wang HY, Pisanò MR, Friedman E. 1994. Attenuated protein kinase C activity and translocation in Alzheimer's disease brain. *Neurobiol Aging* 15:293-298.
- Weinreb O, Bar-Am O, Amit T, Youdim MB. 2004. Neuroprotection via Bcl-2 PKC interaction. *FASEB J* 18:1471-1473.
- Weinstock M, Bejar C, Wang RH, Poltyrev T, Gross A, Finberg J, Youdim MB. 2000. TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease. *J Neural Transm Suppl* 60:157-170.
- Weinstock M, Kirschbaum-Slager N, Lazarovici P, Bejar C, Youdim MB, Shoham S. 2001. Neuroprotective effects of novel cholinesterase inhibitors derived from rasagiline as potential anti-Alzheimer drugs. *Ann N Y Acad Sci* 939:148-161.
- Weinstock M, Poltyrev T, Bejar C, Youdim MB. 2002. Effect of TV3326, a novel monoamine-oxidase cholinesterase inhibitor, in rat models of anxiety and depression. *Psychopharmacology (Berl)* 160:318-324.
- Weinstock M, Poltyrev T, Gross A, Sagi Y, Youdim MB. 2003. A novel cholinesterase and brain selective monoamine oxidase inhibitor for treatment of dementia co-morbid with depression and parkinson's disease. *Prog Neuropsychopharmacol Biol Psychiatry* 27:555-561.
- Yogev-Falach M, Amit T, Bar-Am O, Sagi Y, Weinstock M, Youdim MB. 2002. The involvement of mitogen-activated protein (MAP) kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline. *FASEB J* 16:1674-1676.
- Yogev-Falach M, Amit T, Bar-Am O, Youdim MB. 2003. The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives in MAPK-dependent amyloid precursor protein processing. *FASEB J* 17:2325-2327.
- Youdim MB. 2003. Rasagiline; an anti-Parkinson drug with neuroprotective activity. *Exp Rev Neurotherapeutics* 3:737-749.
- Youdim MB, Amit T, Yogev-Falach M, Bar-Am O, Maruyama W, Naoi M. 2003. The essentiality of Bcl-2, PKC and proteasome-ubiquitin complex activations in the neuroprotective-antiapoptotic action of the anti-Parkinson drug, rasagiline. *Biochem Pharmacol* 66:1635-1641.
- Youdim MB, Gross A, Finberg JP. 2001a. Rasagiline [*N*-propargyl-1*R*(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. *Br J Pharmacol* 132:500-506.
- Youdim MB, Wadia A, Tatton W, Weinstock M. 2001b. The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo. *Ann N Y Acad Sci* 939:450-458.
- Youdim MB, Weinstock M. 2001. Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(*N*-propargyl-(3*R*)aminoindan-5-*YL*)-ethyl methyl carbamate]. *Cell Mol Neurobiol* 21:555-573.
- Yuan J, Yankner BA. 2000. Apoptosis in the nervous system. *Nature* 407:802-809.
- Zanzami N, Brenner C, Marzo I, Susin SA, Kroemer G. 1998. Subcellular and submitochondrial mode of action of Bcl-2-like oncoproteins. *Oncogene* 16:2265-2282.

Full Paper

A Potent Apoptosis-Inducing Activity of a Sesquiterpene Lactone, Arucanolide, in HL60 Cells: a Crucial Role of Apoptosis-Inducing Factor

Yoshihito Nakagawa^{1,*}, Munekazu Iinuma², Nobuyasu Matsuura³, Kong Yi¹, Makoto Naoi¹, Toshihiro Nakayama⁴, Yoshinori Nozawa¹, and Yukihiro Akao¹

¹Gifu International Institute of Biotechnology, 1-1 Naka-Fudogaoka, Kakamigahara, Gifu 504-0838, Japan

²Pharmacognosy, Department of Public Health Pharmacy, Gifu Pharmaceutical University, 5-6-1 Mitahora-higashi, Gifu 502-8585, Japan

³Department of Life Science, Faculty of Science, Okayama University of Science, 1-1, Ridai-cho, Okayama 700-0005, Japan

⁴Gifu Shellac Manufacturing Co., Ltd., 1-41 Higashiuzura, Gifu 500-8168, Japan

Received July 9, 2004; Accepted December 16, 2004

Abstract. Six main sesquiterpene lactones (germacranolides) from *Calea urticifolia* were evaluated for in vitro cytotoxicity against human tumor cell lines HL60 and SW480 cells. Among them, arucanolide and parthenolide displayed marked cytotoxicity against both cell lines. Arucanolide exhibited a low IC₅₀ in HL60 cells. The cytotoxic activity of arucanolide was observed at lower concentrations compared to that of parthenolide, which has been reported to be a typical and simple germacranolide. The activity was found to be mainly due to apoptosis that was assessed by morphological findings, DNA ladder formation (24–36 h), and flow cytometric analysis in HL60 cells. Western blotting and an apoptosis inhibition assay using caspase inhibitors did not demonstrate the activation of any caspases tested. However, the mitochondrial membrane potential of HL60 cells was lost after 24-h treatment with arucanolide, and concurrently apoptosis-inducing factor (AIF) released from mitochondria was detected by Western blot analysis. The inactivation of nuclear factor- κ B, which has been commonly shown in parthenolide-induced apoptosis, did not occur in arucanolide-induced apoptosis. Taken together, the findings presented here indicate that arucanolide induced marked apoptosis in HL60 cells mainly by dissipating mitochondrial membrane potential, which would trigger AIF-induced apoptosis.

Keywords: arucanolide, parthenolide, sesquiterpene lactone, apoptosis, apoptosis-inducing factor

Introduction

Increasing attention has been paid to primitive medicinal plants to find new substances with potentially useful biological activities. Recently, sesquiterpene lactones with a germacrane skeleton were isolated from *Calea urticifolia*, which has been used in El Salvador as a traditional medicinal plant (1), and examined for effects on cytotoxicity. With relation to sesquiterpene lactones, parthenolide, which is the basic germacranolide, is regarded as one of the tumor suppressive agents (2). The bioactive effect of parthenolide is mediated by preventing nuclear factor- κ B (NF- κ B) signaling (3–5).

In the course of our phytochemical study to search for biologically active compounds, five main sesquiterpene lactones from *Calea urticifolia* were subjected to cytotoxic screening. In the present study, we have demonstrated the cytotoxicity in a series of the sesquiterpene lactones, particularly germacranolides against human cultured cancer cells. In addition, we have discussed the structure-activity relationship in these compounds. Furthermore, it was shown that the apoptosis-inducing effect of arucanolide on HL60 cells was mainly caused by loss of the mitochondrial membrane potential and a concurrent apoptosis-inducing factor (AIF) activation, indicating a different mechanism from that in parthenolide-induced apoptosis.

*Corresponding author. FAX: +81-583-71-4412

E-mail: nakagawa@giib.or.jp

Materials and Methods

Plant material

Leaves of *Calea urticifolia* (Miller) DC. were purchased at medicinal market in San Salvador in 1998 and identified by M.I. The voucher specimen has been kept at his laboratory in Gifu Pharmaceutical University (No. EL-091).

Extraction and isolation

The air-dried leaves (170 g) were extracted with acetone by reflux to obtain a crude extract (9.8 g). The extract was suspended in H₂O and extracted with CHCl₃ three times. The concentrated CHCl₃ extract (7.1 g) was subjected to silica gel column chromatography eluted by a CHCl₃-MeOH solvent system from the ratio of 30:1 to 10:1 to give 10 fractions. Fraction 2 (2.1 g) was separated by reversed-phase silica gel column chromatography eluted with 40 and 65% MeOH. A concentrated syrup of 65% MeOH elution was further purified with reversed phase HPLC (Mightysil RP-18 250-20; Kanto Chemical Co., Inc., Tokyo). The HPLC conditions were as follows: flow rate, 11.3 ml/min; detector, 210 nm; solvent, 42% CH₃CN; column oven temperature, 40°C. The values of retention time in min (yield) were as follows: calealactone A, 38.3 (52 mg); 2,3-epoxy-calealactone A, 25.3 (91 mg); calealactone B, 13.5 (30 mg); calealactone C, 20.2 (28 mg); arucanolide, 18.1 (173 mg); juanislinamin, 35.1 (138 mg); and 2,3-epoxy-juanislinamin, 23.3 (195 mg). All isolated compounds have been kept at the laboratory of one of authors (N.M.) in Okayama University of Science (1).

Reagents

Several sesquiterpene lactones with a germacrane skeleton were isolated from leaves of *Calea urticifolia* (Compositae), and their structures were determined (1). Five compounds among them (arucanolide, calealactone A, 2,3-epoxy-calealactone A, calealactone B, and 2,3-epoxy-juanislinamin) and parthenolide as a control were examined against two tumor cell lines. They were prepared in DMSO at the concentration of 10 mM and then further diluted to the working concentration before use. Resveratrol (Sigma-Aldrich Co., St. Louis, MO, USA) was used as a reference because resveratrol, which is a kind of natural polyphenol, is well-known to have strongly cytotoxic activity against cancer cells. Furthermore, arsenic trioxide (Sigma-Aldrich Co.) was used as a reference because it induced caspase-dependent apoptosis in HL60 cells (6, 7).

Cell culture, morphological study, and cell viability

We used two human tumor cell lines. The SW480 cell

line was used as a representative of solid tumor cells (colon cancer) and the HL60 cell line was used as a representative of hematopoietic tumor (leukemia). They were grown in RPMI-1640 medium supplemented with 10% (v/v) heat-inactivated fetal bovine serum (Sigma, Tokyo) and 2 mM L-glutamine under an atmosphere of 95% air and 5% CO₂ at 37°C. Human peripheral blood lymphocytes (PBL) were isolated from blood of healthy donor by centrifuge with Ficoll-Paque Plus (Amasham Biosciences, Uppsala, Sweden). PBL were stimulated with concanavalin-A (15 μg/ml) for 48 h and used for growth suppression of arucanolide or other compounds. The evaluation of cell growth was determined by the trypan blue dye-exclusion assay. For evaluating IC₅₀, the starting cell number was 2 × 10⁵/ml. For evaluating apoptotic cell death, cells were seeded at a density of 2 × 10⁵/ml in 15-mm-diameter wells and cultured for 12 h, and then DNA ladder formation was examined at various times after the start of treatment with the compounds. For morphological examination of apoptotic changes, cells were stained with Hoechst 33342 (5 μg/ml) at 37°C for 30 min, washed twice with phosphate-buffered saline (PBS), pipetted dropwise onto a glass slide, and examined by fluorescence microscopy using a microscope (Olympus, Tokyo) equipped with an epi-illuminator and appropriate filters.

Analysis of DNA fragmentation by agarose gel electrophoresis

Cellular DNA was extracted from whole cells by the procedure described previously (8). RNase was added to the DNA solution at the final concentration of 20 μg/ml, and the mixture was incubated at 37°C for 30 min. After electrophoresis on a 2.5% agarose gel, DNA was visualized by ethidium bromide staining.

Western blot analysis

Before and after treatment with arucanolide, HL60 cells were washed twice with PBS; lysed in lysis buffer A, B, or C, depending on the preparation; and then homogenized. Lysis buffer A (2 × PBS, 0.1% SDS, 1% Nonidet P-40, 0.5% sodium deoxycholate, and 25 × Complete[®], a mixture of protease inhibitors (Roche, Penzberg, Germany)) was used to analyze caspase-3, -8, -9, -2, and BID. Lysis buffer B (250 mM sucrose, 20 mM Hepes-KOH (pH 7.5), 10 mM KCl, 1.5 mM MgCl₂, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, and 25 × Complete[®]) was used to analyze AIF, cytochrome c, and endonuclease G. Lysis buffer C (250 mM sucrose, 20 mM Hepes-KOH (pH 7.5), 10 mM KCl, 1.5 mM MgCl₂, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 1% Nonidet P-40, 25 × Complete[®], and Phosphatase Inhibitor Cocktail[®] 1 and 2 (Sigma-Aldrich Co.)) was

used to analyze MAP kinases, p-I κ B, Bad, p-Bad, and Bcl-xL. The mitochondrial and cytosolic fractions were prepared as reported previously (9). Ten micrograms of protein of each cell lysate was separated by SDS-PAGE by using an adequate percent of polyacrylamide in the gel and electroblotted onto a PVDF membrane (Du Pont, Boston, MA, USA). After blockage of nonspecific binding sites for 1 h by 5% nonfat milk in TPBS (PBS and 0.1% Tween 20), the membrane was incubated overnight at 4°C with various antibodies. They include anti-human caspase-3 (Santa Cruz Biotechnology, Santa Cruz, CA, USA); anti-human caspase-8 (MBL, Nagoya); anti-human caspase-9 (Novus Biologicals Inc., Littleton, CO, USA); anti-human caspase-2 (MBL) and anti-human Bid (Cell Signaling Technology Inc., Beverly, MA, USA); anti-human AIF (ProSci Inc., Poway, CA, USA); anti-human cytochrome c (Upstate Biotechnology Inc., Lake Placid, NY, USA); anti-human endonuclease G (Sigma-Aldrich Co.); anti-human p44/42 MAP kinase (p44/42), anti-human phospho-p44/42 MAPK (Thr202/Tyr204) (p-p44/42), anti-human SAPK/JNK (JNK), anti-human phospho-SAPK/JNK (Thr183/Tyr185) (p-JNK), anti-human p38 MAP kinase (p38), anti-human phospho-p38 MAP kinase (Thr180/Tyr182) (p-p38), anti-human Bad, anti-human phospho-Bad (Ser112) (p-Bad) (Cell Signaling Technology Inc.); anti-human Bcl-xL (H-5) (Santa Cruz Biotechnology); anti-human phospho-I κ B- α (Ser32) (p-I κ B) (Cell Signaling Technology Inc.); and anti-human β -actin (Sigma-Aldrich Co.). The membrane was then washed three times with TPBS, incubated further with alkaline phosphatase-conjugated goat anti-mouse antibody (Promega, Madison, WI, USA), or anti-rabbit antibody (New England Biolabs, Beverly, MA, USA) at room temperature, and then washed three times with TPBS. The immunoblot was visualized by use of an enhanced chemiluminescence detection kit (New England Biolabs).

Inhibition of apoptosis by caspase inhibitors

For the study of inhibition of apoptosis, the tripeptide pan-caspase inhibitor Z-VAD-FMK (MBL), caspase-3 inhibitor Z-DEVD-FMK (MBL), caspase-8 inhibitor Z-IETD-FMK (MBL), or caspase-2 inhibitor Z-VDVAD-FMK (MBL) was added in the culture medium 12 h before treatment with arucanolide. Optimal concentration of the inhibitor was determined from the dose-response curve for the extent of cell death. Each caspase inhibitor was used at the concentrations 50–100 μ M. Inhibition of apoptosis by the inhibitors was evaluated by the blockage of the process of nucleosomal DNA fragmentation, which was observed as ladder formation.

RT-PCR

Before and after treatment with arucanolide, HL60 cells were washed twice with PBS. RT-PCR was performed as described previously (10). In brief, total cellular RNA of HL60 cells was isolated by the phenol/guanidium thiocyanate method with DNase I treatment. By reverse transcription of 2 μ g of total RNA, cDNAs were obtained, and amplification of the respective cDNA region was conducted by PCR. PCR primers were used ApoPrimer Set (Bcl-2 family) (Takara Bio, Inc., Shiga). β -Actin cDNA was used for an internal standard. The PCR reaction consisted of 30 cycles (94°C for 30 s, 57.5°C for 1 min, 72°C for 1 min) after an initial denaturation step (95°C for 1 min). PCR products were analyzed by electrophoresis on 2% agarose gels.

Measurement of mitochondrial membrane potential and assessment of cell death by FACS

Mitochondrial membrane potential was measured by use of a fluorescent dye, Mito-Tracker Green (#M-7514; Molecular Probes, Eugene, OR, USA) that estimates the mitochondrial volume and Mito-Tracker Orange (#M-7511, Molecular Probes) that accumulates selectively in active mitochondria and becomes fluorescent when oxidized. Assessment of cell death was made by using propidium iodide (PI) (MBL) and Annexin V (MBL). The cells were treated with 3, 5, or 6 μ M arucanolide for 24 h. After the cells were washed twice with RPMI-1640 medium, the arucanolide-treated or untreated cells were incubated with Mito-Tracker fluorescent probes, PI, or Annexin V (100 nM each) for 30 min at 37°C. After the cells were collected and washed twice with PBS, the cells were resuspended in PBS. The fluorescence of Mito-Tracker Orange, Green, PI, and Annexin V was analyzed by flow cytometry, respectively (Becton Dickinson, San Jose, CA, USA) (10).

Secreted alkaline phosphatase (SEAP) activity

HeLa cells were cultured in Dulbecco's Eagle's medium (Nissui, Tokyo) containing 10% calf serum (Boehringer Mannheim, Mannheim, Germany) and 100 μ M non-essential amino acid (Invitrogen, Carlsbad, CA, USA) at 37°C. The day before transfection, 5.5×10^4 of HeLa cells were seeded on a 12-well tissue culture plate. pNF- κ B-SEAP (0.3 μ g/well) (BD Biosciences, CA, USA) or pSV-b-GAL (0.3 μ g/well) (Promega) vector was co-transfected with a EffecteneTM transfection reagent (QIAGEN, Hilden, Germany). After 16 h, the medium containing plasmid was exchanged to 1000 μ l of fresh growth medium without serum for 24 h. Arucanolide or parthenolide was added into each well,